At last, the Food and Drug Administration (FDA) is saying what its European counterparts have been saying for the past two years. On October 13, the FDA issued the following press release:
FDA: Possible increased risk of thigh bone fracture with bisphosphonates
Labeling change adds warning about possible risks of long-term use of osteoporosis drugs
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229171.htm
All we can say in the Femur Friends support group (over 50 members, including one man) is, "About time!"
Last May, some of our members met with FDA officials to voice our concerns. Looks like we made our point. Just for the record, we do not think that femur fractures are all that rare. Some thigh-bone (femur) fractures are erroneously classified as hip fractures, which they are not.
